NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin

NVP-BEZ235 is a dual phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) inhibitor. A dual approach targeting more than one downstream effector is a promising strategy for treating cancers. The aim of this study was to evaluate the effect of NVP-BEZ235 in treating FaDu hypopharynge...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Cheng-Ming, Lin, Pai-Mei, Tsai, Yao-Te, Tsai, Ming-Shao, Tseng, Chun-Han, Lin, Sheng-Fung, Yang, Ming-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945618/
https://www.ncbi.nlm.nih.gov/pubmed/29760955
http://dx.doi.org/10.1038/s41420-018-0060-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945618/
https://www.ncbi.nlm.nih.gov/pubmed/29760955
http://dx.doi.org/10.1038/s41420-018-0060-7

Ejemplares similares